You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

PSORCON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Psorcon patents expire, and when can generic versions of Psorcon launch?

Psorcon is a drug marketed by Taro Pharms North and Pfizer and is included in three NDAs.

The generic ingredient in PSORCON is diflorasone diacetate. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the diflorasone diacetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Psorcon

A generic version of PSORCON was approved as diflorasone diacetate by AVONDALE PHARMS on April 27th, 1999.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PSORCON?
  • What are the global sales for PSORCON?
  • What is Average Wholesale Price for PSORCON?
Summary for PSORCON
US Patents:0
Applicants:2
NDAs:3
Raw Ingredient (Bulk) Api Vendors: 59
Patent Applications: 5,950
DailyMed Link:PSORCON at DailyMed
Drug patent expirations by year for PSORCON

US Patents and Regulatory Information for PSORCON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharms North PSORCON diflorasone diacetate CREAM;TOPICAL 020205-001 Nov 20, 1992 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer PSORCON diflorasone diacetate OINTMENT;TOPICAL 019260-001 Aug 28, 1985 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pfizer PSORCON E diflorasone diacetate OINTMENT;TOPICAL 017994-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PSORCON

See the table below for patents covering PSORCON around the world.

Country Patent Number Title Estimated Expiration
Australia 468257 ⤷  Sign Up
Japan S5227760 PRODUCTION OF NOVEL COMPOUND AND COMPOSITION ⤷  Sign Up
Japan S52113954 LOCAL PHARMACEUTICAL AGENT CONTAINING CLINDAMYCINE ⤷  Sign Up
Germany 2308731 ⤷  Sign Up
Denmark 133382 ⤷  Sign Up
South Africa 7700943 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.